Medincell Collaborates with AbbVie for the Development of Therapies Across Various Indications
Shots:
- Medincell and AbbVie have entered into a strategic licensing agreement to co-develop & commercialize up to 6 candidates by utilizing Medincell's long-acting injectable technology platform. The 1st LAI program is selected with its formulation underway
- Under the agreement, Medincell is entitled to receive $35M up front, $1.9B development & commercial milestones ($315M each) along with mid-single to low-double-digit net-sales-based royalties
- Furthermore, Medincell will be responsible for formulation activities & preclinical development to advance the candidates into clinical evaluation while AbbVie will fund and handle the clinical development, regulatory approval, manufacturing & commercialization
Ref: Medincell | Image: Medincell
Related News:- AbbVie Receives the MHRA’s Marketing Authorisation of Aquipta (atogepant) for the Prevention of Migraines in Adults
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
